Cocrystal Pharma, Inc. Stock price

Equities

COCP

US19188J4094

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.5 USD +0.73% Intraday chart for Cocrystal Pharma, Inc. -1.32% -12.90%
Sales 2023 * - Sales 2024 * - Capitalization 15.26M
Net income 2023 * -19M Net income 2024 * -22M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.72 x
P/E ratio 2024 *
-0.59 x
Employees 12
Yield 2023 *
-
Yield 2024 *
-
Free-Float 69.97%
More Fundamentals * Assessed data
Dynamic Chart
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates CI
Top Premarket Gainers MT
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A CI
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cocrystal Pharma Files $150 Million Mixed Shelf MT
HC Wainwright Adjusts Cocrystal Pharma's Price Target to $12 From $35, Keeps Buy Rating MT
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cocrystal Pharma Files $150 Million Mixed Shelf MT
Cocrystal Pharma, Inc. Appoints Fred Hassan to Its Board of Directors CI
Cocrystal Pharma, Inc. announced that it has received $4.000002 million in funding from Frost Gamma Investments Trust CI
Insider Buy: Cocrystal Pharma MT
Cocrystal Pharma, Inc. announced that it expects to receive $4.000002 million in funding from Frost Gamma Investments Trust and other investor CI
More news
1 day+0.73%
1 week-1.32%
Current month+4.90%
1 month+3.49%
3 months-14.77%
6 months-23.47%
Current year-12.90%
More quotes
1 week
1.46
Extreme 1.455
1.55
1 month
1.40
Extreme 1.4
1.58
Current year
1.33
Extreme 1.325
1.89
1 year
1.33
Extreme 1.325
3.29
3 years
1.33
Extreme 1.325
41.52
5 years
1.33
Extreme 1.325
41.52
10 years
1.33
Extreme 1.325
550.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 14-01-01
Chief Executive Officer 58 17-02-22
Chairman 77 14-01-01
Members of the board TitleAgeSince
Director/Board Member 87 14-01-01
Director/Board Member 68 21-05-26
Director/Board Member 63 14-01-01
More insiders
Date Price Change Volume
24-03-27 1.5 +0.73% 11,756
24-03-26 1.489 -0.72% 7,185
24-03-25 1.5 -1.96% 8,274
24-03-22 1.53 +1.32% 4,944
24-03-21 1.51 -0.66% 13,369

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
Cocrystal Pharma, Inc. is a biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. It is developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It also uses advanced computational methods to screen and design product candidates using proprietary cocrystal structural information. The Company's pipeline CC-42344 is an oral PB2 inhibitor discovered using Cocrystals proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus replication machinery is targeted.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.5 USD
Average target price
8 USD
Spread / Average Target
+433.33%
Consensus
  1. Stock
  2. Equities
  3. Stock Cocrystal Pharma, Inc. - Nasdaq